linagliptin/metformin hydrochloride
Jentadueto · ATC code A10BD11
Also known as: Linagliptin/Metforminhydrochlorid, Linagliptin / Metformin Hydrochloride · Brand names: Jentadueto, Ilinpru Combi, Linagliptin/Metformin, Dialipta Met, Dianovia Met, Linatin Met, Liniga Plus, Lintrejamet, Snoxx-Met
- Key facts
- Active substance
- linagliptin/metformin hydrochloride (INN: linagliptin / metformin hydrochloride)
- Drug class
- Anti-diabetic medication
- ATC code
- A10BD11
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Jentadueto 2.5 mg/850 mg film-coated tablets / Jentadueto 2.5 mg/1 000 mg film-coated tablets
- Marketing authorisation holder
- Boehringer Ingelheim International GmbH
- Information as of
- 2026-10-27
Key facts
Linagliptin/metformin hydrochloride (Jentadueto) is a fixed combination of a DPP-4 inhibitor and metformin. It is used in adults with type 2 diabetes as an adjunct to diet and exercise.
What it is used for
- Type 2 diabetes in adults inadequately controlled on their maximally tolerated dose of metformin
- In combination with other diabetes medicines, including insulin
- Patients already taking linagliptin and metformin as separate tablets
Dosing
- Linagliptin 2.5 mg twice daily (5 mg total daily dose) plus the metformin dose already taken
- Maximum 5 mg linagliptin plus 2,000 mg metformin hydrochloride daily
- With a sulphonylurea or insulin: a lower dose of these may be required to reduce hypoglycaemia risk
- Renal impairment: maximum metformin dose depends on GFR; metformin is contraindicated below GFR 30 mL/min
- Assess GFR before starting and at least annually; not recommended in hepatic impairment
Contraindications
- GFR < 30 mL/min (metformin contraindicated)
- Not to be used in type 1 diabetes
- Hepatic impairment: not recommended
Important warnings
- Lactic acidosis: very rare but serious, mostly with acute worsening of renal function, cardiorespiratory illness or sepsis
- In dehydration (severe diarrhoea, vomiting, fever) temporarily stop metformin
- Hypoglycaemia when combined with a sulphonylurea or insulin
- Monitor renal function, particularly in the elderly
Side effects
- Most frequent: diarrhoea (1.6%)
- Common: vitamin B12 decrease/deficiency, taste disturbance
- Uncommon: nasopharyngitis, hypersensitivity, cough, decreased appetite
- Hypoglycaemia very common with a sulphonylurea; lactic acidosis very rare
Interactions
- Sulphonylureas and insulin: increased hypoglycaemia risk
- Linagliptin is a P-glycoprotein substrate and weak CYP3A4 inhibitor; interactions with other P-gp substrates unlikely
Pregnancy and breastfeeding
- Linagliptin not studied in pregnant women; limited metformin data show no increased risk of congenital malformations
Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- JentaduetoBoehringer Ingelheim International GmbH · EMEA/H/C/002279
Source: European Medicines Agency (EMA), product information
Austria
- Ilinpru CombiViatris Limited · 1 register entry
- Linagliptin/MetforminStada Arzneimittel Gmbh, 1a Pharma Gmbh, Sandoz Gmbh, Hcs Bvba · 5 register entries
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Turkey
- Dialipta MetALİ RAİF İLAÇ SAN. A.Ş. · 2 register entries
- Dianovia MetBİOFARMA İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
- Linatin MetNOBEL İLAÇ SAN. VE TİC. A.Ş. · 3 register entries
- Liniga PlusGENVEON İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
- LintrejametSANDOZ İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
- Snoxx-MetSANOVEL İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16
Brand names in 23 more European countries
- Bulgaria
- Ilinpru Combi, Linatin Met, Илинпру Комби, Лимерексо, Линаглиптин/Метформин Чайкафарма, Линатин Мет
- Croatia
- Autnami, Lymerexo
- Cyprus
- Autnami, Linagliptin/Metformin Tad
- Czechia
- Linagliptin/Metformin Sandoz, Linagliptin/Metformin Stada, Lymerexo
- Denmark
- Glymetia, Liglifev, Marsialo, Nagilma
- Estonia
- Autnami, Linagliptin/Metformin Stada, Lymerexo
- Finland
- Linagliptin/Metformin Krka, Linagliptin/Metformin Sandoz
- Greece
- Alfalib, Linagliptin+metformin Stada, Lymerexo, Nagilma, Μarsialo
- Hungary
- Autnami, Ilinpru Combi, Linagliptin-Metformin Linagliptin-Metformin Stada, Linagliptin-Metformin Stada, Linagliptin/Metformin
- Iceland
- Jentadueto
- Ireland
- Linagliptin/Metformin Hydrochloride Rowex
- Italy
- Linagliptin E Metformina Eg, Linagliptin E Metformina Sandoz
- Latvia
- Autnami, Linagliptin/Metformin Stada, Lymerexo
- Liechtenstein
- Jentadueto
- Lithuania
- Autnami, Linagliptin/Metformin Stada, Lymerexo
- Malta
- Glymetia, Linagliptin/Metformin Clonmel, Linagliptin/Metformin Doc, Linagliptin/Metformin Galenicum, Linagliptin/Metformin Hcl Pharos, Linagliptin/Metformin Kern Pharma, Linagliptin/Μetformin Sandoz, Ma25508401, Mirugu
- Netherlands
- Liglifev
- Norway
- Jentadueto
- Poland
- Autnami, Linagliptin + Metformin Hydrochloride Stada, Linagliptin+metformin Hydrochloride Stada, Lymerexo
- Portugal
- Metformina + Linagliptina Alter, Metformina + Linagliptina Krka, Metformina + Linagliptina Mylan, Metformina + Linagliptina Ripzen, Metformina + Linagliptina Sandoz, Metformina + Linagliptina Tad
- Slovakia
- Linagliptin/Metformin Stada, Mirugu
- Slovenia
- Liglipexcombi, Linagliptin/Metformin Krka, Lymerexo
- Spain
- Linagliptina/Metformina Cinfa, Linagliptina/Metformina Combix, Linagliptina/Metformina Krka, Linagliptina/Metformina Sandoz, Linagliptina/Metformina Stada, Linagliptina/Metformina Tarbis
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Related calculators
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Jentadueto – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/jentadueto-epar-product-information_en.pdf
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
- Wikidata (CC0): ATC A10BD.
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.